GoAI
Get started
Pediatrix Medical Group, Inc. logo

Pediatrix Medical Group, Inc.

MD

NYSEHealthcareMedical - Care Facilities

Open in GoAI

Previous close

$26.57

+$0.35 · +1.33%

Aug 21, 4:00 PM ET

MD company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

89

Deep Value

Momentum

63

Gaining

Sentiment

68

Bullish

Risk resilience

77

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Pediatrix Medical Group, Inc. delivers specialized medical services for newborns, expectant mothers, and pediatric patients across the United States and Puerto Rico. The company offers crucial neonatal care to critically ill or prematurely born infants within hospital units, staffed by expert neonatal subspecialists and advanced practice clinicians. For pregnant individuals and their developing babies, Pediatrix provides comprehensive maternal-fetal medicine services in both clinical and inpatient settings, involving specialists such as maternal-fetal medicine physicians, obstetricians, and genetic counselors. Furthermore, the group delivers pediatric cardiology services, addressing both congenital and acquired heart conditions in patients ranging from the fetal stage through adulthood, under the care of dedicated pediatric cardiologists. Beyond these core areas, Pediatrix extends its expertise to various other pediatric subspecialties, including those requiring intensivists, surgeons, and ophthalmologists, and supplies vital support to hospital departments like emergency rooms and labor and delivery units. Established in 1979 in Sunrise, Florida, and formerly known as MEDNAX, Inc. until its renaming in July 2022, the company managed a network of approximately 2,700 physicians as of February 2022.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
US
CEO
Mark S. Ordan
Listed since
Sep 20, 1995
Employees
4,280

Market position

Day range

Current $26.57

52-week range

Current $26.57

Open
$26.20
Previous close
$26.22
Volume
717.44K
0.88× average
Average volume
814.44K
Average daily volume
Market cap
2.18B USD
Beta
0.65
Market reference 1
50-day average
$25.7332
+3.25% above average
200-day average
$22.7619
+16.73% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.11B USD
P/E (TTM)
12.59×
P/B (TTM)
2.4×
P/S (TTM)
1.12×
EV / EBITDA
7.69×
Earnings yield
9.07%
Free cash flow yield
13.85%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
25.95%
Operating margin
11.60%
Net margin
8.96%
Return on equity
19.10%
Return on assets
7.36%
Return on invested capital
9.67%

Financial health

Debt / equity
0.7×
Current ratio
1.66×
Altman Z-score
2.42
Piotroski F-score
7 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends30%17%5%-8%Gross margin, FY2021: 26.85%Gross margin, FY2022: 23.68%Gross margin, FY2023: 21.13%Gross margin, FY2024: 22.57%Gross margin, FY2025: 24.66%Operating margin, FY2021: 10.62%Operating margin, FY2022: 8.76%Operating margin, FY2023: 0.37%Operating margin, FY2024: -3.41%Operating margin, FY2025: 12.07%Net margin, FY2021: 6.85%Net margin, FY2022: 3.36%Net margin, FY2023: -3.03%Net margin, FY2024: -4.92%Net margin, FY2025: 8.64%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 26.85%. Gross margin FY2022 23.68%. Gross margin FY2023 21.13%. Gross margin FY2024 22.57%. Gross margin FY2025 24.66%. Operating margin FY2021 10.62%. Operating margin FY2022 8.76%. Operating margin FY2023 0.37%. Operating margin FY2024 -3.41%. Operating margin FY2025 12.07%. Net margin FY2021 6.85%. Net margin FY2022 3.36%. Net margin FY2023 -3.03%. Net margin FY2024 -4.92%. Net margin FY2025 8.64%.

Income trends

Revenue

1.91B USD-4.92%

Operating income

231.09M USD+299.8M USD

Net income

165.39M USD+264.46M USD
Income trends across reported periods2.22B USD1.38B USD534.53M USD−310.27M USDRevenue, FY2021: 1.91B USDRevenue, FY2022: 1.97B USDRevenue, FY2023: 1.99B USDRevenue, FY2024: 2.01B USDRevenue, FY2025: 1.91B USDOperating income, FY2021: 202.92M USDOperating income, FY2022: 172.69M USDOperating income, FY2023: 7.32M USDOperating income, FY2024: −68.71M USDOperating income, FY2025: 231.09M USDNet income, FY2021: 130.96M USDNet income, FY2022: 66.34M USDNet income, FY2023: −60.41M USDNet income, FY2024: −99.07M USDNet income, FY2025: 165.39M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.91B USD. Revenue FY2022 1.97B USD. Revenue FY2023 1.99B USD. Revenue FY2024 2.01B USD. Revenue FY2025 1.91B USD. Operating income FY2021 202.92M USD. Operating income FY2022 172.69M USD. Operating income FY2023 7.32M USD. Operating income FY2024 −68.71M USD. Operating income FY2025 231.09M USD. Net income FY2021 130.96M USD. Net income FY2022 66.34M USD. Net income FY2023 −60.41M USD. Net income FY2024 −99.07M USD. Net income FY2025 165.39M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.91B USD2.01B USD1.99B USD1.97B USD1.91B USD
Cost of goods sold1.44B USD1.56B USD1.57B USD1.5B USD1.4B USD
Gross profit471.88M USD454.34M USD421.57M USD467.03M USD513.24M USD
Selling, general, and administrative240.79M USD238.44M USD227.54M USD231.4M USD263.36M USD
Operating expenses240.79M USD523.06M USD414.24M USD294.35M USD310.32M USD
Interest income19.05M USD————
Interest expense35.97M USD40.74M USD42.08M USD39.7M USD68.72M USD
Depreciation and amortization21.83M USD32.23M USD36.17M USD35.64M USD32.15M USD
Operating income231.09M USD−68.71M USD7.32M USD172.69M USD202.92M USD
Net income165.39M USD−99.07M USD−60.41M USD66.34M USD130.96M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 1 miss, 1 met estimate
Average EPS surprise
+18.30%
11 comparable reports
Latest EPS result
0.63
Estimate 0.59 · Beat by 6.60%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.710.540.380.21Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 20, 2025: actual 0.51, estimate 0.37, surprise +37.84%, Beat. Q2 2025, reported May 6, 2025: actual 0.33, estimate 0.25, surprise +32.00%, Beat. Q3 2025, reported Aug 5, 2025: actual 0.53, estimate 0.42, surprise +26.19%, Beat. Q4 2025, reported Nov 3, 2025: actual 0.67, estimate 0.46, surprise +45.65%, Beat. Q1 2026, reported Feb 19, 2026: actual 0.5, estimate 0.53, surprise -5.66%, Miss. Q2 2026, reported May 5, 2026: actual 0.44, estimate 0.37, surprise +18.92%, Beat. Q3 2026, reported Aug 4, 2026: actual 0.63, estimate 0.591, surprise +6.60%, Beat. Q4 2026, reported Nov 2, 2026: actual —, estimate 0.63, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates522.46M494.39M466.33M438.26MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 20, 2025: actual 502.36M USD, estimate 473.27M USD, surprise +6.15%, Beat. Q2 2025, reported May 6, 2025: actual 458.36M USD, estimate 459.74M USD, surprise -0.30%, Miss. Q3 2025, reported Aug 5, 2025: actual 468.84M USD, estimate 473.67M USD, surprise -1.02%, Miss. Q4 2025, reported Nov 3, 2025: actual 492.88M USD, estimate 486.23M USD, surprise +1.37%, Beat. Q1 2026, reported Feb 19, 2026: actual 493.77M USD, estimate 486.23M USD, surprise +1.55%, Beat. Q2 2026, reported May 5, 2026: actual 476.2M USD, estimate 465.83M USD, surprise +2.23%, Beat. Q3 2026, reported Aug 4, 2026: actual 487.78M USD, estimate 478.49M USD, surprise +1.94%, Beat. Q4 2026, reported Nov 2, 2026: actual —, estimate 498.18M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$26.60

0.11% upside
Past 12 months12-month forecastHigh $28.00Average $26.60Low $24.00

Rating distribution

33 ratings
Strong buy00%
Buy1339%
Hold1855%
Sell26%
Strong sell00%

Recent analyst actions

7 institutions
Leerink PartnersmaintainMarket Perform
MacquariemaintainOutperform

MD news

zacks.com

Here's Why Pediatrix Medical Group (MD) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read source
zacks.com

Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio

MD's stronger cash collections, favorable payer mix, acquisitions and telehybrid care support its growth prospects.

Read source
zacks.com

Here's Why Pediatrix Medical Group (MD) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read source
zacks.com

Pediatrix Medical Tops Q2 Earnings on Better Cash Collections

MD posts a Q2 earnings beat as stronger cash collections and a favorable payor mix lift results despite lower volumes.

Read source
marketbeat.com

Pediatrix Medical Group Q2 Earnings Call Highlights

Pediatrix Medical Group NYSE: MD reported second-quarter 2026 adjusted EBITDA of $76 million and reaffirmed its full-year adjusted EBITDA outlook of $280 million to $300 million, as stronger revenue-cycle-management…

Read source
seekingalpha.com

Pediatrix Medical Group, Inc. (MD) Q2 2026 Earnings Call Transcript

Pediatrix Medical Group, Inc. (MD) Q2 2026 Earnings Call Transcript

Read source

Corporate actions

Corporate action history

Stock split

Effective Dec 20, 2013

2:1

Stock split

Effective Apr 28, 2006

2:1

Stock split

Effective Mar 1, 1999

2:1

MD peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,254.77

+0.83%

Johnson & Johnson logo

JNJ

Johnson & Johnson

$270.24

+1.07%

AbbVie Inc. logo

ABBV

AbbVie Inc.

$265.01

+1.21%

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$152.55

+2.39%

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$390.11

+1.37%

Novartis AG logo

NVS

Novartis AG

$158.86

+1.68%

ETFs holding MD

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
128.42M
Weight
0.11%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$147.31+0.64%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
69.69M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
56.22M
Weight
0.07%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
50.06M
Weight
0.03%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Value ETF logoVanguard Morningstar Small-Cap Value ETFVBR
Market value
31.79M
Weight
0.05%
AUM
68.3B USD
Expense ratio
0.05%
Price / 1D
$249.18+0.68%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
24.51M
Weight
0.03%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
20.49M
Weight
0.14%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
State Street SPDR Portfolio S&P 600 Small Cap ETF logoState Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Market value
19.76M
Weight
0.12%
AUM
17.03B USD
Expense ratio
0.03%
Price / 1D
$57.28+0.61%

Continue in GoAI

Research MD

research.disclaimer